Selective PI3K delta inhibitors
The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
1. A compound selected from
(S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one
and pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable carrier.
3. A method for the treatment of leukemia comprising the step of administering to a subject in need thereof an effective amount of the compound of claim 1 .
4. The method of claim 3 , further comprising the step of administering simultaneously or sequentially to a subject in need thereof at least one other anti-cancer agent.
5. The compound of claim 1 , wherein the compound has an enantiomeric excess of at least 98%.
6. The method of claim 3 , wherein the leukemia is chronic lymphocytic leukemia (CLL).
7. The method of claim 3 , wherein the leukemia is acute lymphocytic leukemia.
8. The method of claim 3 , wherein the leukemia is acute myelocytic leukemia (AML).
9. The method of claim 3 , wherein the leukemia is promyelocytic leukemia.
10. The method of claim 3 , wherein the leukemia is chronic myelogenous leukemia.
11. (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one.
12. The compound of claim 11 , wherein the compound has an enantiomeric excess of at least 98%.
13. A pharmaceutical composition comprising a compound of claim 11 and at least one pharmaceutically acceptable carrier.
14. A method for the treatment of leukemia comprising the step of administering to a subject in need thereof an effective amount of the compound of claim 11 .
15. The method of claim 14 , further comprising the step of administering simultaneously or sequentially to a subject in need thereof at least one other anti-cancer agent.
16. The method of claim 14 , wherein the leukemia is chronic lymphocytic leukemia (CLL).
17. The method of claim 14 , wherein the leukemia is acute lymphocytic leukemia.
18. The method of claim 14 , wherein the leukemia is acute myelocytic leukemia (AML).
19. The method of claim 14 , wherein the leukemia is promyelocytic leukemia.
20. The method of claim 14 , wherein the leukemia is chronic myelogenous leukemia.